The company’s new division, DelNaturals, seeks to bridge the gap between natural beauty standards and clinical performance. While legacy brands have relied on aluminum salts for over a century, SECCO utilizes a proprietary, plant-derived ingredient blend developed through the firm's existing research pipeline. By targeting perspiration at its source rather than simply masking odor, the brand intends to establish a new category in premium personal care.

Dr. Kathy Fields, known for co-founding Proactiv and Rodan + Fields, provides both scientific validation and commercial expertise to the venture. Her involvement signals a shift toward evidence-based consumer goods, moving away from the fragrance-focused marketing typical of the sector. CEO Mary Gardner noted that the company is actively courting investors who prioritize intellectual property and rigorous R&D over traditional beauty branding.

This move follows DelNova’s broader corporate strategy to diversify its output. While its primary therapeutic asset, ReViVox, remains focused on the multi-billion-dollar botulinum toxin market, the launch of SECCO provides a near-term commercial application for the company's technology. The firm is positioning this deodorant as the first in a series of planned expansions into high-end, science-backed personal care products.